跳至主要内容
临床试验/CTIS2023-504384-16-00
CTIS2023-504384-16-00招募中1 期

Prospective study to evaluate the efficacy of letermovir prophylaxis for the prevention of CMV infection in lung transplant recipients compared to a retrospective cohort treated with standard valganciclovir prophylaxis for 12 months (LETERCOR Study) - FCO-LET-2022-01

Fundacion Para La Investigacion Biomedica De Cordoba0 个研究点目标入组 70 人开始时间: 2023年6月5日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • 18 years and older, Lung transplant patients (D+/R-) pre-transplant, Have an undetectable PCR-CMV within 96 hours prior to the start of letermovir prophylaxis (prospective cohort), Patients who have given their written informed consent (prospective cohort), Patients treated with valganciclovir prophylaxis for 12 months (retrospective cohort), Patients transplanted in the 2 years prior to the start of the study (retrospective cohort), Patients with a complete follow-up of 13 months and with comparable data with respect to the prospective cohort that allow the evaluation of the main variables of the study (retrospective cohort)

排除标准

  • HIV-infected patients, Multivisceral transplant patients, Patients who cannot comply with the study protocol (prospective cohort), Receiving an antiviral prophylaxis other than ganciclovir prior to letermovir prophylaxis (prospective cohort), Patients with simultaneous renal and hepatic insufficiency (prospective cohort)

研究者

相似试验

Prospective study to evaluate the efficacy of... | 临床试验